Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BIBF 1120 vs BIBW 2992 vs sequential BIBF 1120 → BIBW 2992 in hormone-resistant prostate cancer
2005-005249-21Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) comparing BIBF 1120, BIBW 2992 and Sequential BIBF 1120 → BIBW 2992 (3 arms). Primary endpoint: 12-week progression-free rate. Started Jan 2006; status: completed.
02
Drugs
nintedanibafatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005249-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005249-21.